B of A Securities Downgrades AMPH to Sell with $20 Price Target

B of A Securities has downgraded AMPH to a sell rating, setting a price target of $20. This change was announced on June 29, 2026, by analyst Jason Gerberry. Shares of AMPH traded around $21.78 on Monday, reflecting the market's reaction to this updated outlook.

Other Institutional Activity in AMPH

Several institutional investors have recently adjusted their positions in AMPH. BlackRock, Inc. slightly reduced its holdings by 40,672 shares, ending with about 5.42 million shares valued at approximately $106.2 million. Dimensional Fund Advisors LP increased its stake by 228,262 shares to hold just over 2 million shares worth about $39.7 million. State Street Corp also boosted its position by 75,729 shares, totaling roughly 1.6 million shares valued at $31.5 million. Vanguard Capital Management LLC opened a new position with 1.54 million shares valued at $30.2 million. Meanwhile, TD Asset Management Inc cut its holdings by 422,008 shares, leaving it with about 1.54 million shares worth $30.2 million.

Amphastar Pharmaceuticals, Inc. Stock Down 8.2%

Shares of AMPH traded near $21.78 on Monday. With the recent analyst downgrade, the market may be assessing its future potential more cautiously. The stock has seen varied interest from major institutional investors, suggesting a mix of confidence and caution.

Insider Buying and Selling at Amphastar Pharmaceuticals, Inc.

Recent insider activity at AMPH included several purchases in early June. On June 1, insiders Richard Prins, Michael Zasloff, Diane Gerst, Gayle Deflin, and David Russell Gaugh each acquired 8,143 shares. Additionally, on the same day, Richard Prins and David Russell Gaugh bought 17,365 shares each. On June 2, Lee Howard sold 769 shares at an average price of $18.45.

Analysts Set New Price Targets

B of A Securities' downgrade to a sell with a $20 target was part of a broader trend among analysts. On June 3, Barclays maintained its hold rating with a $20 target. Earlier, Wells Fargo downgraded the stock to hold with a $19 target on May 14, while Piper Sandler reiterated a hold rating with a $21 target on May 11. The consensus among analysts reflects cautious optimism, with a mean target price leaning around the $20 mark.

Bottom Line

B of A Securities' downgrade of AMPH to a sell with a $20 target highlights concerns about the company's near-term prospects. Despite this, institutional investors have shown mixed actions in their positions, signaling varied expectations. Insider buying in early June suggests some confidence from within the company, while analysts remain divided on its future performance. Investors will continue to watch AMPH as new developments unfold.